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Abstract The mitochondrial pyruvate oxidation route is a
tightly regulated process, which is essential for aerobic cellu-
lar energy production. Disruption of this pathway may lead to
severe neurometabolic disorders with onset in early child-
hood. A frequent finding in these patients is acute and chronic
lactic acidemia, which is caused by increased conversion of
pyruvate via the enzyme lactate dehydrogenase. Under stable
clinical conditions, this process may remain well compensated
and does not require specific therapy. However, especially in
situations with altered energy demands, such as febrile infec-
tions or longer periods of fasting, children with mitochondrial
disorders have a high risk of metabolic decompensation with
exacerbation of hyperlactatemia and severe metabolic acido-
sis. Unfortunately, no controlled studies regarding therapy of
this critical condition are available and clinical outcome is
often unfavorable. Therefore, the aim of this review was to
formulate expert-based suggestions for treatment of these
patients, including dietary recommendations, buffering strat-
egies and specific drug therapy. However, it is important to
keep in mind that a specific therapy for the underlying meta-
bolic cause in children with mitochondrial diseases is usually
not available and symptomatic therapy especially of severe
lactic acidosis has its ethical limitations.
Introduction
Mitochondria play a central role in the production of ATP via
the process of oxidative phosphorylation (OXPHOS). Basi-
cally, this biochemical system consists of the respiratory chain
enzymes (mitochondrial complex I–IV), which are coupled to
ATP synthase (complex V). Disruption of this pathway may
lead to severe neurodegenerative disorders. The overall inci-
dence of mitochondrial diseases is estimated at 1–5 in 10,000
live births, making this one of the commonest inherited errors
of metabolism (Thorburn 2004; Schaefer et al 2008). The
umbrella term Bmitochondriopathy^ comprises a large number
of heterogeneous diseases with diverse clinical phenotypes.
This aspect is further illustrated by the fact that to date,
disease-causing mutations have been identified in more than
230 different genes (Koopman et al 2012; Rotig 2014). The
resulting biochemical defects may affect any OXPHOS com-
plex (isolated or as a combined deficiency). Moreover, coen-
zyme Q10 metabolism and pyruvate oxidation including pyru-
vate dehydrogenase complex (PDHC) may be impaired. In
addition, secondary mitochondrial disorders may arise from
an indirect impairment of OXPHOS function (for example
alterations in cardiolipin metabolism as in Barth syndrome
[OMIM:302060], disturbance of mitochondrial protein import
as inMohr-Tranebjaerg syndrome [OMIM:304700], inhibition
of the respiratory chain in organic acidurias like propionic
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acidemia [OMIM:606054] or impaired uptake of cofactors of
the OXPHOS system). In this review the term mitochondrial
diseases is used for disorders affecting aerobic energy metab-
olism with a main focus on OXPHOS defects.
In general, although no good correlation exists between
the biochemical defect measured in tissue samples or cul-
tured skin fibroblasts and clinical disease expression, se-
vere biochemical OXPHOS defects mostly present already
in the neonatal period or in young infants, leading to rapid
deterioration and death in early childhood (Baertling et al
2014). Clinical phenotypes include fatal neonatal lactic
acidosis, classical Leigh syndrome (OMIM:256000),
Leigh-like syndrome, and Alpers-Huttenlocher syndrome
(OMIM:203700).
From a biochemical perspective, dysfunction of OXPHOS
enzymes causes a relative increase in the production of ATP
via anaerobic glycolysis, leading to intracellular accumulation
of pyruvate and NADH. Under aerobic conditions, pyruvate is
converted into acetyl-CoA and further oxidized via the Krebs
cycle. The first irreversible reaction of glucose oxidation is
catalyzed by PDHC (Mizock 1989). Therefore the activity of
PDHC determines whether pyruvate is oxidized to CO2 and
H2O or converted either to lactate via lactate dehydrogenase or
to alanine via alanine transaminase (or alanine aminotransfer-
ase; ALAT) (Felig 1973). The activity of the PDHC is
modulated by reversible phosphorylation. PDHC is
inactivated by phosphorylation catalyzed by a PDH kinase
(in humans there exist four distinct isoforms of this enzyme:
PDK1-4), the latter of which is stimulated byATP, NADH and
acetyl-CoA. Two specific PDHC phosphatases dephosphory-
late the complex and reactivate it. PDHC is further controlled
by end-product inhibition (Patel and Korotchkina 2006). In
the case of disturbances of the respiratory chain, NADH may
accumulate in the cells (Enns et al 2000) leading to an inhibi-
tion of the PDH followed by an activation of lactate dehydro-
genase, resulting in a regeneration of NAD+ and subsequent
elevation of lactate (an overview of lactate metabolism is
depicted in Fig. 1).
Accordingly, hyperlactatemia is a common feature among
children with mitochondrial disorders (Robinson 2006). Es-
pecially in situations with altered energy requirements, such as
febrile infections or longer periods of fasting, patients with
mitochondrial disorders have a high risk of a severe aggrava-
tion of hyperlactatemia with metabolic decompensation. Un-
fortunately, acute metabolic crisis is often difficult to control
in these children and may have a rapidly fatal course (Koene
et al 2012; Leary et al 2013). This is mainly based on the fact
that treatment of lactic acidosis in mitochondrial disorders is
only symptomatic and causal treatment options are very lim-
ited (Pfeffer et al 2012).
Fig. 1 Lactate metabolism and basic concepts of small molecule
interventions. Pyruvate is the end-product of glycolysis and degradation
of small amino acids like alanine. In the presence of oxygen, it is
transported into mitochondria via a pyruvate transporter (PT), where
it is converted to acetyl-CoA catalyzed by the pyruvate
dehydrogenase complex (PDHC) and finally oxidized to CO2.
PDH may be inactivated through phosphorylation by pyruvate
dehydrogenase kinase (PDK). PDK can be inactivated by the drug
dichloroacetate (DCA). On the other hand, where there is hypoxia or
impaired function of the respiratory chain, pyruvate is reduced to
lactate via lactate dehydrogenase (LDH). Thus, NAD+ required for
glycolysis is regenerated. Accumulated lactate is released from the
cell, which may cause acidosis. The buffer solution sodium
bicarbonate (Na+ + HCO3−) acts via the reaction of bicarbonate
with protons. The resulting CO2 is exhaled, thereby reducing
a c i d o s i s . T h e am i n e g r o u p o f t h e b u f f e r s o l u t i o n
Tris(hydroxymethyl)aminomethane (THAM) takes up one proton
and the protonated form of THAM is eliminated via the kidneys
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Pathophysiology of lactic acidosis
Of note, lactate per se is not toxic and there is even evidence
for a neuroprotective effect (Berthet et al 2009; Wyss et al
2011). However, excessive lactate levels and severe/
prolonged metabolic acidosis have finally deleterious effects
on many cellular functions:
1) Cardiovascular system: Increased proton concentrations
in blood lead to decreased cardiac contractility, which is
caused by reduced myofilament calcium sensitivity and
lowered influx of calcium into the cells (Orchard and
Kentish 1990). Furthermore, arterial vasodilation with
simultaneous constriction of venous vessels occurs during
acidosis (Mitchell et al 1972; Kellum et al 2004a, b). At
the same time, acidosis leads to stimulation of the sym-
pathetic nervous system. The functional consequences are
pH dependent. At pH values above 7.2, cardiac contrac-
tility increases due to enhanced release of catecholamines.
However, at pH values below 7.2, opposite effects are
observed (Mitchell et al 1972). Generally, tissue response
to catecholamines is decreased during acidosis (Huang
et al 1995). In addition, a closure of gap junctions slows
the impulse conduction of the heart and leads to a high
incidence of arrhythmias (Orchard and Cingolani 1994).
2) Respiratory system: By stimulation of peripheral and
central chemoreceptors, breathing rate increases due to
the elevated concentration of protons in order to compen-
sate for metabolic acidosis (O’Regan and Majcherczyk
1982). The high energy consumption of this process may
lead to respiratory decompensation after prolonged
acidosis.
3) Central nervous system (CNS): To correct intracellular
acidosis, different cerebral membrane transporters are
activated, leading to an intracellular accumulation of
Na+ and Cl−. This results in an increased influx of water
into the cells. As a consequence, cerebral edema may
develop (Staub et al 1996).
4) Immune system: An additional systemic effect of acidosis
is a reduced immune response with increased susceptibil-
ity to serious infections caused by an elevated release of
interleukins from macrophages and impaired leukocytes
function (Lardner 2001; Kellum et al 2004a, b).
5) Endocrine system: The response of the cells is pH depen-
dent. Insulin resistance increases at pH <7.2 and normal-
izes above (Walker et al 1963). Impaired insulin sensitiv-
ity of the cells is probably caused by a pH-dependent
binding of insulin to its receptor (Cuthbert and Alberti
1978).
6) General effects: Multiple organs are limited in their func-
tion during prolonged acidosis, which leads to decreased
tissue oxygenation, impaired ATP production and in-
creased apoptosis (Halperin et al 1994).
Management of lactic acidosis in children
with mitochondrial disorders
There are no controlled studies on treatment of lactic acidosis
in children with mitochondrial diseases. Recommendations in
the literature are primarily based on retrospective analyzes in
children with lactic acidosis in the context of shock, sepsis or
unknown underlying conditions (Hatherill et al 2003; Bever-
idge and Wilkinson 2006; Aschner and Poland 2008; Berg
et al 2010; Parker and Parshuram 2013). While lactate eleva-
tions associated with shock or sepsis are mainly due to tissue
hypoperfusion, and treatment of the underlying causes is most
important to manage this condition, hyperlactatemia due to
primary mitochondrial dysfunctions is caused by an impaired
cellular energy metabolism with usually no causal treatment
available. Accordingly, intensive care management of these
patients constitutes a major challenge. Against this back-
ground, the aim of this review was to formulate expert-based
suggestions for treatment of lactic acidosis in children with
mitochondrial disorders. However, based on the lack of well-
designed controlled studies, the level of evidence is unfortu-
nately low. Therefore, our recommendations only represent a
consensus between our clinical centers and specific details
may be handled differently. Moreover, despite the treatment
options described in the following sections, it is essential to
keep in mind that therapy specific for the underlying metabol-
ic cause is usually not available. Acute metabolic crisis may
cause irreversible brain damage that severely affects quality of
life. Therefore, decision-making regarding intensive care
treatment might differ from patient to patient and should be
done in close interaction with the family. If available, involve-
ment of a specialized palliative care team should be
considered.
Fluid management during metabolic crisis
Initially, normocaloric feeding and adequate fluid supplemen-
tation should be administered orally or via gastric tube. If this
is not possible due to the poor clinical condition of the patient
during metabolic crisis, early placement of a central venous
line for buffering and parenteral nutrition is required. Catab-
olism should be avoided. However, infusion therapy should
be done with caution since high glucose supplementation/
glucose bolus application might worsen lactic acidosis
(Prietsch et al 2002). As a starting point, we suggest starting
infusion at a moderate glucose rate of 5–6mg/kg/min (of note,
the infusion rate might be optimized depending on age and
clinical condition) (Sheridan et al 1998; Prietsch et al 2002).
Serum glucose and lactate levels should be monitored closely
after start of infusion therapy. After starting infusion therapy,
further steps depend on close clinical re-assessment of the
patient. If tolerated well, glucose rate might be further in-
creased up to 7–8 mg/kg/min. Importantly, a parallel increase
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in glucose and lactate levels may indicate disturbed glucose
utilization and the infusion rate should be lowered according-
ly. In our experience, serum glucose levels should not exceed
values between 100 and 120 mg/dl (5.6–6.7 mmol/L). The
application of additional insulin to lower glucose levels and to
increase cellular glucose uptake should only be used with
caution because it might worsen the intracellular glucose
utilization problem and aggravate acidosis. Moreover, labora-
tory monitoring of the critical balance between glucose and
lactate levels becomes unreliable under these conditions and
further therapeutic decisions may be hindered. Generally, if
glucose infusion is not tolerated well, increased administration
of fat (2–3 g/kg/day) should be tried to achieve adequate
calorie supplementation. Of note, during the acute crisis, fat
intake above 3 g/kg/day should be avoided because evidence
from the literature suggests that an increased NADH/NAD+
ratio generated by reduced flux through the respiratory chain
leads to a secondary inhibition of β-oxidation (Infante and
Huszagh 2000). Importantly, in patients (especially neonates)
where the differential diagnosis of a fatty acid oxidation
disorders is not yet excluded, administration of fat should be
avoided.
Specific treatment options
Unfortunately, causal treatment for children with mitochon-
drial diseases is usually not available. Nevertheless, specific
interventions should be considered in certain conditions. In
patients where the etiology of the lactic acidosis is unclear,
several (not exclusively mitochondrial) metabolic diseases/
transporter defects should also kept in mind. For most of the
supplementations listed below no well-designed clinical trials
have been performed and the results of the often anecdotic
reports summarized below should be read in this context
(Pfeffer et al 2013).
1) Thiamine supplementation might be effective in thia-
mine respons ive PDHC def ic iency or th iamine
pyrophosphokinase deficiency (dosage: 15–30 mg/kg/day;
(Mayr et al 2011)). Moreover, thiamine (and biotin) adminis-
tration may be life saving in unclear disease conditions with
possible differential diagnoses of thiamine deficiency
(Manzanares and Hardy 2011) or thiamine metabolism disor-
ders (biotin-thiamine-responsive basal ganglia disease;
(Distelmaier et al 2013)). 2) Riboflavin supplementation was
shown to improve the clinical status of patients with mito-
chondrial complex I deficiency caused by ACAD9 mutations
(dosage: 10 mg/kg/day up to max. 300 mg/day) (Gerards et al
2011). To date the mechanism of these therapeutic effects is
not sufficiently clear. It might act as cofactor and also has
electron donor and acceptor properties and may thus interfere
with the respiratory chain (Tarnopolsky and Raha 2005). 3)
Coenzyme Q10 application should be considered in suspected
coenzyme Q10 deficiency (OMIM:607426) disorders (dosage:
5–20 mg/kg/day up to max. 1 g/day) (Rotig et al 2000). To
increase coenzyme Q10 oral bioavailability, application of a
self-emulsifiable composition is recommended (Sato et al
2013). 4) Carnitine supplementation should be provided in
cases of secondary carnitine deficiency (dosage: 50–
100 mg/kg/day). 5) Ketogenic diet is well established as
therapy for patients with PDHC deficiency and has neuropro-
tective, antiepileptic and mitochondriotropic effect also for
other mitochondrial diseases (Wexler et al 1997; Klepper
et al 2002). It is contraindicated in patients with known fatty
acid oxidation disorders and pyruvate carboxylase deficiency.
6) Phenylbutyrate therapy might be a future option to treat
lactic acidosis especially in patients with PDHC deficiency
(Ferriero et al 2013). However, human studies are lacking so
far. 7) Some patients with pyruvate carboxylase deficiency
may profit from administration of biotin or from an
anaplerotic diet containing 130 cal/kg/day with 30 % of glu-
cose, 30 % of long-chain fatty acids, 5 % of protein, and 35 %
of triheptanoin (Mochel et al 2005; Roe and Mochel 2006).
Furthermore different anaplerotic substrates are tried for ther-
apy of pyruvate carboxylase deficiency including high doses
of citrate (7.5 mmol/kg/day) (Ahmad et al 1999). 8) Biotini-
dase deficiency can be successfully treated by administering
biotin (dosage: 10–20 mg/day) (Bousounis et al 1993; Wolf
2012). For an overview see also Table 1. Details regarding
mitochondrial medications and supplements are also given in
the review of Parikh et al (2009).
Buffer therapy during metabolic acidosis
There is conflicting literature on the effects of infusing a buffer
solution duringmetabolic acidosis (Kecskes and Davies 2002;
Andrade et al 2007; Lim 2007; Kraut and Madias 2012). This
debate is a consequence of the lack of controlled studies
regarding benefits, side effects and outcome of this therapy,
especially in the context of rare metabolic diseases. Neverthe-
less, based on the idea that severe acidosis may cause cellular
tissue damage and the fact that respiratory compensation via
hyperventilation is an energy consuming process, buffer ther-
apy is frequently used during severe lactic acidosis.
Recommendations regarding timing of initiation of therapy
differ in the literature and range from pH values <7.2 down to
pH<7.0 (Andrade et al 2007; Lim 2007; Sabatini and
Kurtzman 2009; Kraut and Madias 2012). However, many
patients are able to maintain normal pH values via excessive
hyperventilation. This creates a critical condition, which
might decompensate later on. Therefore, it is essential that
pH values, pCO2 levels and base deficit are monitored in
parallel. Importantly, rapid correction of blood pH may wors-
en cerebral acidosis since abrupt suppression of hyperventila-
tion stimuli may cause increased blood pCO2, which crosses
the blood brain barrier faster than HCO3
−. As a consequence,
brain oedema may develop (Herrera and Kazemi 1980; Staub
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et al 1996). Therefore, buffering should be started rather early
at a slow infusion rate. The initial hours of buffer therapy
should be monitored closely with regular blood gas analyses.
Of note, in situations of severe metabolic acidosis and de-
creased blood pressure, capillary blood sampling becomes
unreliable and arterial blood gas analyses should be
performed.
Sodium bicarbonate buffering
Sodium bicarbonate buffering is the most commonly used
therapy for the management of acidosis due to different dis-
orders. After injection, sodium bicarbonate dissociates to Na+
and HCO3
−. Of these two, hydrogen carbonate takes up pro-
tons to form CO2 and water. Acidosis can be subsequently
reduced by exhalation of CO2 (for basic mechanism see also
Fig. 1).
Of note, sodium bicarbonate buffering has several side
effects, including hypernatremia, volume overload, exacerba-
tion of intracellular acidosis, hyperosmolality and potential
deve lopment of ce r ebra l edema , hypoka lemia ,
hypocalcaemia, and reduced cardiac contractility (Glaser
et al 2001).
To minimize negative effects of sodium bicarbonate, there
are several recommendations to its application. 1) If possible,
i soosmot ic so lu t ions should be used , whereby
hyperosmolality may be prevented (Lim 2007). However,
volume overload should be avoided. 2) To minimize the
increase in the intracellular acidosis, a slow application rate
is recommended (see below), although there are no studies in
humans available (Kecskes and Davies 2002).
To calculate the quantity of required bicarbonate volume,
the distribution of bicarbonate is equated to the extracellular
body fluid. In young children, this corresponds to 50–70 % of
body weight. Often, the administration of 30 % is sufficient to
stabilize the metabolic situation and to minimize potential side
effects. This results in the following two formulas (Debray
et al 2007):
HCO3
− mmolð Þ ¼ HCO3− target value½  – HCO3− initial value½ ð Þ
 body weight kgð Þ  0:3
or
HCO3
− mmolð Þ ¼ BE 0:3 body weight kg; :ð Þ
The value of 0.3 is derived from the 30 % described above.
Importantly, in neonates a value of 0.4 and in preterm infants a
value of 0.5 should be inserted in the calculations.When using
Table 1 Drugs and supplements that might be beneficial in children with suspected mitochondrial disease and metabolic crisis
Thiamine Biotin Riboflavin Coenzyme Q10 L-carnitine
Mode of action Cofactor of several
enzymes
including PDHC
Enzyme cofactor Enzyme cofactor;
electron donor and
acceptor properties
Cofactor of the
electron
transport chain;
antioxidant
properties
Facilitates fatty acyl
group transport into
mitochondria;
maintains
the ratio of acyl-CoA
to free CoA
Dosage 15–30 mg/ body
weight (kg)/day
15 mg/ body
weight (kg)/day
10 mg/ body weight
(kg)/day up to max.
300 mg/day
5–20 mg/ body weight
(kg)/day up
to max. 1 g/day
50–100 mg/ body
weight (kg)/day
Administration Intravenous and
oral application
possible
Oral application Intravenous and oral
application possible
Oral application Usually oral
application,
intravenous
application is also
possible
Main
indications
Thiamine
deficiency or
thiamine
metabolism
disorders;
PDHC deficiency
Biotin-thiamine-
responsive basal
ganglia disease;
biotinidase
deficiency
Mitochondrial complex I
deficiency (ACAD9
mutations); multiple
acyl CoA dehydrogenase
deficiency; may be helpful
also in other mitochondrial
diseases
Suspected
coenzyme Q10
deficiency disorders;
mitochondrial
myopathies
Mitochondrial
myopathies;
secondary carnitine
deficiency
Main side
effects
Generally
considered safe;
dermatitis may
occur after
intravenous
application
Rarely, allergic skin
reaction may occur
May rarely cause
anorexia and
nausea
It may increase the
risk of bleeding;
may lower blood
sugar levels; may
cause gastrointestinal
distress; may cause
sleep disruption
Gastrointestinal
distress; Bfishy^
body odour; allergic
reactions are rare;
rarely, seizures may
occur
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an undiluted 8.4 % solution for infusion (1 ml = 1 mmol
sodium bicarbonate) it should be administrated through a
central venous system due to its high osmolarity. Depending
on the severity of acidosis and clinical condition, half of the
calculated sodium bicarbonate amount can be infused over 1–
2 h. The remaining amount should be infused at a slower rate.
Importantly, blood gases should be monitored closely, espe-
cially during the initial buffering phase (for an overview see
Table 2).
THAM (Tris-hydroxymethyl-amino-methane) buffering
THAM is a Na+-free buffer solution that can be used in
conditions of respiratory or metabolic acidosis (Nahas et al
1998). Importantly, THAM does not generate increased CO2
levels, which is ideal in situations where CO2 elimination is
impaired (Nahas et al 1998). During lactic acidosis, THAM
reacts according to the following chemical equation: R-NH2 +
H+ + Lactate− = > R-NH3
+ + Lactate−. The protonated R-
NH3
+ is eliminated via the kidneys (for the basic mechanism
see also Fig. 1).
Despite some advantages, THAM is used less frequently
than bicarbonate for buffer therapy during metabolic acidosis
because several potential side effects including,
hyperkalaemia, hypoglycaemia, hepatotoxicity, apnoea/
hypopnoea, and skin necrosis after extravasation may occur
(Roberton 1970; Nahas et al 1998; Holmdahl et al 2000;
Gehlbach and Schmidt 2004).
In children with mitochondrial disease and severe lactic
acidosis, THAM buffering might be an alternative where the
affected individual is hypernatraemic, which limits the use of
bicarbonate. The THAM dosage can be calculated according
to the following equation (Kraut and Madias 2012): THAM
(amount in ml of a 0.3 mol/L solution) = body weight (kg) x
base deficit (HCO3
− [target value] – HCO3
− [initial value]) ×
1.1. It is recommended that the calculated THAM dose is
infused at a slow rate (at least 1 h). The maximum daily dose
is 15 mmol/kg for an adult patient. However, in newborns
THAM dosage should not exceed 5–7 mmol/kg body weight
because of the reduced kidney function (for an overview see
Table 2).
Sodium citrate buffering
Sodium citrate buffering is mainly used for long-term treat-
ment of patients with chronic metabolic acidosis. However, it
might also be considered in the acute situation depending on
the clinical condition of the patient and the wishes of the
family (e.g. intravenous buffering has several side effects
and may require a central venous catheter, etc.). After oral
application, sodium citrate leads to a decrease in blood proton
levels and a parallel increase in HCO3
− concentrations (for the
defined underlying mechanism see (Kowalchuk et al 1989)).
Compared with oral sodium bicarbonate application, sodium
citrate does not induce gastrointestinal gas production and is
usually better tolerated (McNaughton 1990). Based on our
experience, therapy can be started with a dosage between 0.5
and 1.0 mmol/kg/day (divided into three doses). Further dos-
ages should be adjusted according to blood gas analyses (for
an overview see Table 2).
Dichloroacetate therapy
Dichloroacetate stimulates the enzyme pyruvate dehydroge-
nase kinase, and in doing so, the enzyme pyruvate dehydro-
genase remains in its unphosphorylated catalytically active
Table 2 Symptomatic drug treatment of acute and chronic lactic acidosis
Sodium bicarbonate THAM Sodium citrate Dichloroacetate
Type of acidosis Acute Acute Chronic Acute and chronic
Mode of action Extracellular buffering
of protons with
generating CO2
Extra- and intracellular buffering of
protons without generating CO2
Extracellular buffering of
protons with generating
CO2
Intracellular reduction of lactate
production via stimulation of
pyruvate dehydrogenase kinase
Dosage HCO3
− (mmol) = base
excess × 0.3 × body
weight (kg)
THAM (ml of a 0.3 mol/L solution)
= body weight (kg)
× base deficit (mmol/L) × 1.1
0.5 to 1 mmol/body weight
(kg)/day
(divided into three doses)
25 mg/body weight (kg)/day
(divided into two doses)
Administration Slow intravenous infusion
of the first half of the
amount over 1–2 h
Slow intravenous infusion over 1 h Oral application Oral application; in
exceptional cases
intravenous application
possible (see main text)
Main side effects Exacerbation of intracellular
acidosis; hypernatremia;
hypokalemia;
hypocalcaemia;
reduced cardiac
contractility; local injury
in cases of extravasation
Hyperkalemia; hypoglycaemia;
respiratory depression; liver
necrosis in newborns; local
injury in cases of extravasation
Hypernatremia;
muscle spasms;
gastrointestinal
distress
Peripheral neuropathy;
liver dysfunction
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state (Stacpoole 1989). The resulting pyruvate is mainly con-
verted via the Krebs cycle and lactate production decreases
(for the basic mechanism see also Fig. 1). Dichloroacetate
crosses the blood–brain barrier effectively and can be used
in cases of chronic as well as acute lactic acidosis (Berendzen
et al 2006; Kaufmann et al 2006; Stacpoole et al 2008a, b). For
long-term administration in children, a dose of 25mg/kg/d has
been recommended (Abdelmalak et al 2013). A single report
described the application of intravenous dichloroacetate dur-
ing acute lactic acidosis in a preterm newborn with
septicaemia using a dose of 50 mg/kg twice daily (Arnon
et al 2001) (for an overview see Table 2). In general,
dichloroacetate therapy is tolerated well in most cases and
may lead to short-term improvement. However, long-term use
may induce peripheral neuropathy, and there have been no
studies showing clear benefits of long term DCA usage on the
overall disease prognosis (Kurlemann et al 1995; Kaufmann
et al 2006). A promising future option could be
phenylbuytrate, which has a comparable mode of action but
potentially less side effects (Ferriero et al 2013). However,
clinical studies are required to evaluate this therapy.
Renal replacement therapy
Hemofiltration or hemodialysis can potentially be used
for treatment of lactic acidosis. However, these are
invasive procedures with the risk of side effects (see
below). Moreover, they may not be feasible in unstable
patients. Therefore, the use of these approaches should
be critically assessed and might only be applied to
exceptional cases.
In general, several studies dealing with the use of renal
replacement therapy in critical situations of inborn errors of
metabolism demonstrated the successful use of hemofiltration
or hemodialysis to remove toxic substrates (McBryde et al
2006; Tsai et al 2014a, b). Possible advantages of using a renal
replacement therapy over buffering with alkalizing substrates
include the prevention of hyperosmolality and volume over-
load. Furthermore, the effect of alkalizing on ionized calcium
concentration can be reduced by providing calcium. Renal
replacement therapy leads to a quick removal of lactate but a
rebound can occur. In addition, renal replacement therapy
might be the treatment of choice in conditions with lactic
acidosis in combination with hyperammonemia, for example
in patients with mitochondrial complex V deficiency due to
TMEM70 mutations (Honzik et al 2010).
Experienced personnel are required to perform renal
replacement therapy, as it is technically challenging.
Reliable vascular access is needed to allow adequate
blood flow. The placement of catheters can be compli-
cated by vascular stenosis, thrombosis, air emboli, or
hemorrhage. A smaller vascular access in combination
with lower flow rates of the blood in children increase
the risk of clotting (Basu et al 2011; Bridges et al
2012). Systemic anticoagulation can result in a higher
risk of developing hemorrhage. Furthermore, it might
happen that the required rapid volume shifts are not
well tolerated by small or critically ill children with
hemodynamic instability (Tsai et al 2014a, b). Addition-
ally, there is a risk of disequilibrium syndrome caused
by an osmotic gradient between plasma and the brain
because of a fast removal of urea leading to cerebral
edema accompanied with potential death (Kennedy et al
1962; Arieff 1994). Thus, although renal replacement
therapy has some advantages over buffering, it should
only be performed in regard of the risks and by an
experienced team.
Therapeutic hypothermia
Therapeutic hypothermia (TH) has been shown to be neu-
roprotective in newborns suffering neonatal encephalopa-
thy after perinatal asphyxia (Jacobs et al 2013). However,
the role of TH in mitochondrial disease remains unknown.
Rango et al (2014) suggested that brain temperature might
be reduced in patients with mitochondrial disease due to
malfunctioning OXPHOS (Rango et al 2014). They hy-
pothesized that this could be one of the reasons for impaired
neurological outcome in these patients. Whether children
would benefit from TH during a phase of cellular stress and
severe lactic acidosis remains to be analysed in preclinical
and clinical studies, and no clear recommendation can be
given at this stage.
Conclusions
Metabolic crisis and severe lactic acidosis in children with
mitochondrial diseases are a challenging situation. Adequate
caloric supply is essential for these patients. Although
discussed still somewhat controversial, buffer therapy is a
mainstay of lactic acidosis management. For this purpose,
different buffer solutions are available including sodium bi-
carbonate, THAM, and sodium citrate. Buffering should be
started rather early at a slow infusion rate. In addition,
dichloroacetate may be used to lower lactate levels. Of note,
in certain disease conditions, the application of thiamine
(alone or in combination with biotin) might improve the
clinical condition (e.g. thiamine deficiency, thiamine metabo-
lism disorders, thiamine responsive pyruvate dehydrogenase
deficiency). In cases of uncontrollable lactic acidosis (espe-
cially in combination with hyperammonemia), hemofiltration
therapy might be an option. Importantly, despite these symp-
tomatic treatment options, prognosis is often unfavorable,
which should be discussed openly with the relatives.
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